H D Shewade1, S Govindarajan2, P Thekkur3, C Palanivel4, M Muthaiah2, A M V Kumar5, V Gupta6, B N Sharath7, J P Tripathy1, K Vivekananda2, G Roy4. 1. International Union Against Tuberculosis and Lung Disease (The Union) South-East Asia Office, New Delhi, India. 2. State TB Cell, Directorate of Health Services, Puducherry, India. 3. Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India ; Department of Community Medicine, Mahatma Gandhi Medical College and Research Institute, Puducherry, India. 4. Department of Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India. 5. International Union Against Tuberculosis and Lung Disease (The Union) South-East Asia Office, New Delhi, India ; The Union, Paris, France. 6. International Union Against Tuberculosis and Lung Disease (The Union) South-East Asia Office, New Delhi, India ; Department of Community Ophthalmology, All India Institute of Medical Sciences, New Delhi, India. 7. Department of Community Medicine, Employee's State Insurance Corporation Medical College, Bengaluru, India.
Abstract
Setting: A mixed-methods operational research (OR) study was conducted to examine the diagnosis and treatment pathway of patients with presumptive multidrug-resistant tuberculosis (MDR-TB) during 2012-2013 under the national TB programme in Puducherry, India. High pre-diagnosis and pre-treatment attrition and the reasons for these were identified. The recommendations from this OR were implemented and we planned to assess systematically whether there were any improvements. Objectives: Among patients with presumptive MDR-TB (July-December 2014), 1) to determine pre-diagnosis and pre-treatment attrition, 2) to determine factors associated with pre-diagnosis attrition, 3) to determine the turnaround time (TAT) from eligibility to testing and from diagnosis to treatment initiation, and 4) to compare these findings with those of the previous study (2012-2013). Design: This was a retrospective cohort study based on record review. Results: Compared to the previous study, there was a decrease in pre-diagnosis attrition from 45% to 24% (P < 0.001), in pre-treatment attrition from 29% to 0% (P = 0.18), in the TAT from eligibility to testing from a median of 11 days to 10 days (P = 0.89) and in the TAT from diagnosis to treatment initiation from a median of 38 days to 19 days (P = 0.04). There is further scope for reducing pre-diagnosis attrition by addressing the high risk of patients with human immunodeficiency virus and TB co-infection or those with extra-pulmonary TB not undergoing drug susceptibility testing. Conclusion: The implementation of findings from OR resulted in improved programme outcomes.
Setting: A mixed-methods operational research (OR) study was conducted to examine the diagnosis and treatment pathway of patients with presumptive multidrug-resistant tuberculosis (MDR-TB) during 2012-2013 under the national TB programme in Puducherry, India. High pre-diagnosis and pre-treatment attrition and the reasons for these were identified. The recommendations from this OR were implemented and we planned to assess systematically whether there were any improvements. Objectives: Among patients with presumptive MDR-TB (July-December 2014), 1) to determine pre-diagnosis and pre-treatment attrition, 2) to determine factors associated with pre-diagnosis attrition, 3) to determine the turnaround time (TAT) from eligibility to testing and from diagnosis to treatment initiation, and 4) to compare these findings with those of the previous study (2012-2013). Design: This was a retrospective cohort study based on record review. Results: Compared to the previous study, there was a decrease in pre-diagnosis attrition from 45% to 24% (P < 0.001), in pre-treatment attrition from 29% to 0% (P = 0.18), in the TAT from eligibility to testing from a median of 11 days to 10 days (P = 0.89) and in the TAT from diagnosis to treatment initiation from a median of 38 days to 19 days (P = 0.04). There is further scope for reducing pre-diagnosis attrition by addressing the high risk of patients with human immunodeficiency virus and TB co-infection or those with extra-pulmonary TB not undergoing drug susceptibility testing. Conclusion: The implementation of findings from OR resulted in improved programme outcomes.
Authors: A D Harries; J Michongwe; T E Nyirenda; J R Kemp; S B Squire; A R Ramsay; P Godfrey-Faussett; F M Salaniponi Journal: Int J Tuberc Lung Dis Date: 2004-02 Impact factor: 2.373
Authors: A M Kilale; B J Ngowi; G S Mfinanga; S Egwaga; B Doulla; A M V Kumar; M Khogali; J van Griensven; A D Harries; R Zachariah; S G Hinderaker Journal: Public Health Action Date: 2013-06-21
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: A M V Kumar; H D Shewade; J P Tripathy; N Guillerm; K Tayler-Smith; S Dar Berger; K Bissell; A J Reid; R Zachariah; A D Harries Journal: Public Health Action Date: 2016-01-04
Authors: H D Shewade; S Govindarajan; B N Sharath; J P Tripathy; P Chinnakali; A M V Kumar; M Muthaiah; K Vivekananda; A K Paulraj; G Roy Journal: Public Health Action Date: 2015-06-21
Authors: Sarabjit S Chadha; B N Sharath; Kishore Reddy; Jyothi Jaju; P H Vishnu; Sreenivas Rao; Malik Parmar; Srinath Satyanarayana; Kuldeep Singh Sachdeva; Nevin Wilson; Anthony D Harries Journal: PLoS One Date: 2011-11-02 Impact factor: 3.240
Authors: Neeta Singla; Srinath Satyanarayana; Kuldeep Singh Sachdeva; Rafael Van den Bergh; Tony Reid; Katherine Tayler-Smith; V P Myneedu; Engy Ali; Donald A Enarson; Digamber Behera; Rohit Sarin Journal: PLoS One Date: 2014-07-24 Impact factor: 3.240
Authors: H D Shewade; K S Shringarpure; M Parmar; N Patel; S Kuriya; S Shihora; N Ninama; N Gosai; R Khokhariya; C Popat; H Thanki; B Modi; P Dave; R K Baxi; A M V Kumar Journal: Public Health Action Date: 2018-06-21